adaptive biotechnologies stock analysis
Real time Adaptive Biotechnologies Corporation ADPT stock price quote stock graph news analysis. November 3 2022 335 PM 3 min read Adaptive Biotechnologies ADPT came out with a quarterly loss of 032 per share versus the Zacks Consensus Estimate of a loss of.
Adpt 10k 20201231 Htm
Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of 185 million to 190 million compared to the previous expectation of 185 million to 195.
. Adaptive Biotechnologies technical analysis gives you the. According to 15 stock analysts the average 12-month stock price forecast for ADPT stock is 1267 which predicts an increase of 6285. Adaptive Announces Partnership with Epic to Increase.
Piper Sandler Adjusts Price Target on Adaptive Biotechnologies to 750 From 12 Maintains Neutral Rating. As of the 3rd of April Adaptive Biotechnologies shows the risk adjusted performance of 013 and Mean Deviation of 435. Earnings per share EPS surpassed analyst estimates by 16.
Adaptive Biotechnologies Stock analysis including Adaptive Biotechnologies investment evaluation stock information alerts predictive tools such as market volatility and liquidity. You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial. See Adaptive Biotechnologies Corporation ADPT stock analyst estimates including earnings and revenue EPS upgrades and downgrades.
September 19 2022. Detailed financial statements for Adaptive Biotechnologies ADPT including the income statement balance sheet and cash flow statement. The lowest target is 758 and.
The company has 38618 million in cash and 11134 million in debt giving a net cash position of 27484 million or 185 per share. The Adaptive Biotechnologies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations Crowd Wisdom Hedge. Adaptive Biotechnologies Corporation NASDAQADPT traded at 763 at close of the session on Friday 091622 made a downward.
Find the latest Adaptive Biotechnologies Corporation ADPT stock analysis from Seeking Alphas top analysts. A high-level overview of Adaptive Biotechnologies Corporation ADPT stock. Adaptive Biotechnologies EPS Beats Expectations Revenue was in line with analyst estimates.
Stay up to date on the latest stock price chart news analysis fundamentals trading and. Exclusive research and insights from bulls and bears. 1 week ago - Adaptive Biotechnologies ADPT Reports Q2 Loss Tops Revenue Estimates - Zacks Investment Research 1 week ago - Adaptive Biotechnologies Reports.
ADPT Stock Overview Adaptive Biotechnologies Corporation a commercial-stage company develops an immune medicine platform for the diagnosis and treatment of various.
Billion Dollar Seattle Company Adaptive Biotechnologies Lays Off 100 The Seattle Times
Ichor Blood Services Signs Exclusive Agreement With Adaptive Biotechnologies To Bring T Detect Covid T Cell Test To Canada
Adpt 10k 20201231 Htm
Stock Market Shrinkage Exacerbated By Europe Ipos At Decade Low Bnn Bloomberg
Adaptive Biotechnologies Good Buy For Long Term Investors Adpt Seeking Alpha
Adaptive Biotechnologies Good Buy For Long Term Investors Adpt Seeking Alpha
Adaptive Biotechnologies Plans To Sell Up To 9 2m Shares Revenue Grew 52 In 2019 Geekwire
Single Cell T Cell Landscape And T Cell Receptor Repertoire Profiling Of Aml In Context Of Pd 1 Blockade Therapy Nature Communications
Adaptive Biotechnologies Corporation Adpt Stock Price News Info The Motley Fool
Adaptive Biotechnologies Corporation Adpt Stock Price News Info The Motley Fool
Adpt Adaptive Biotechnologies Corp Stock Overview U S Nasdaq Barron S
As Adaptive Biotechnologies Corporation S Nasdaq Adpt Market Cap Dropped By Us 51m Insiders Who Sold Us 514k Worth Of Stock Were Able To Offset Their Losses Simply Wall St News
Tech Stocks Soar In 2020 Amid Pandemic As Seattle Area Companies See Valuations Spike Geekwire
Adaptive Biotechnologies Funding Financials Valuation Investors
Adaptive Biotechnologies Good Buy For Long Term Investors Adpt Seeking Alpha
Biotech Stocks Are Getting Crushed But Industry Insiders Say There S Reason For Optimism Geekwire
Adaptive Biotechnologies Adpt Reports Q3 Loss Lags Revenue Estimates
Adaptive Biotechnologies A Platform Play For Immune Driven Medicine Nasdaq Adpt Seeking Alpha
Ijfs Free Full Text Stock Market Analysis A Review And Taxonomy Of Prediction Techniques Html